Melanoma Clinical Trials

Showing 441-460 of 705 trials

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

NCT02431572

This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called \[11C\] PBR28a, which is also known as peripheral benzodiazepine receptors (PBR), or PBR-PET.

Intracranial TumorsGlioblastomaMelanoma

Massachusetts General Hospital11 participantsStarted May 2015

Boston, Massachusetts, United States • Boston, Massachusetts, United States

UNKNOWNPHASE1

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

NCT04357509

This is an open-lable, single-arm, single-dose escalation and multiple-dose expansion clinical study of cell therapy to observe and evaluate the tolerance, pharmacokinetic characteristics, safety and efficacy of ScTIL210（Super circulating tumor infiltrating lymphocytes）in the treatment of Melanoma.

Melanoma

Peking University Cancer Hospital & Institute32 participantsStarted May 2020

Beijing, Beijing Municipality, China

COMPLETEDPHASE1

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse+4 more

Pfizer190 participantsStarted Jun 2011

Duarte, California, United States • La Jolla, California, United States • La Jolla, California, United States +39 more locations

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Related Searches

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Peginterferon and TIL Therapy for Metastatic Melanoma

Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma